Bacterial CpG-DNA aggravates immune complex glomerulonephritis: role of TLR9-mediated expression of chemokines and chemokine receptors.
Immune complex glomerulonephritis (GN) often deteriorates during infection with viruses and bacteria that, in contrast to mammals, have DNA that contains many unmethylated CpG motifs. Balb/c mice with horse apoferritin-induced GN (HAF-GN) were treated with either saline, CpG-oligodeoxynucleotides (ODN), or control GpC-ODN. Only CpG-ODN exacerbated HAF-GN with an increase of glomerular macrophages, which was associated with massive albuminuria and increased renal MCP-1/CCL2, RANTES/CCL5, CCR1, CCR2, and CCR5 mRNA expression. CpG-ODN induced a Th1 response as indicated by serum anti-HAF IgG(2a) titers, mesangial IgG(2a) deposits, and splenocyte IFN-gamma secretion. Messenger RNA for the CpG-DNA receptor Toll-like reeptor 9 (TLR9) was present in kidneys with HAF-GN but not in normal kidneys. The source of TLR9 mRNA in HAF-GN could be infiltrating macrophages or intrinsic renal cells, e.g., mesangial cells; but, in vitro, only murine J774 macrophages expressed TLR9. In J774 cells, CpG-ODN induced the chemokines MCP-1/CCL2 and RANTES/CCL5 and the chemokine receptors CCR1 and CCR5. It is concluded that CpG-DNA can aggravate preexisting GN via a shift toward a Th1 response but also by a novel pathway involving TLR9-mediated chemokine and chemokine receptor expression by macrophages, which may contribute to the enhanced glomerular macrophage recruitment and activation. This mechanism may be relevant during infection-triggered exacerbation of human immune-complex GN and other immune-mediated diseases in general.
Anders
Hans-Joachim
HJ
Nephrological Center, Medical Policlinic, University of Munich, Munich, Germany.
Banas
Bernhard
B
Linde
Yvonne
Y
Weller
Lars
L
Cohen
Clemens D
CD
Kretzler
Matthias
M
Martin
Stefan
S
Vielhauer
Volker
V
Schlöndorff
Detlef
D
Gröne
Hermann-Josef
HJ
D000818:Animals; D000917:Antibody Formation; D002460:Cell Line; D018925:Chemokines / Q000378:metabolism; D004269:DNA, Bacterial / Q000235:genetics*; D004268:DNA-Binding Proteins / Q000378:metabolism; D005260:Female; D005921:Glomerulonephritis / Q000235:genetics* / Q000503:physiopathology*; D007105:Immune Complex Diseases / Q000235:genetics* / Q000503:physiopathology*; D007668:Kidney / Q000378:metabolism; D008264:Macrophages / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D009838:Oligodeoxyribonucleotides / Q000378:metabolism*; D012333:RNA, Messenger / Q000378:metabolism; D054389:Receptors, CCR1; D019713:Receptors, CCR5 / Q000235:genetics; D011956:Receptors, Cell Surface / Q000378:metabolism; D019707:Receptors, Chemokine / Q000235:genetics / Q000378:metabolism; D018417:Th1 Cells / Q000276:immunology; D014018:Tissue Distribution; D051217:Toll-Like Receptor 9
C515300:CCR1 protein, human; C408982:CPG-oligonucleotide; C515301:Ccr1 protein, mouse; D018925:Chemokines; D004269:DNA, Bacterial; D004268:DNA-Binding Proteins; D009838:Oligodeoxyribonucleotides; D012333:RNA, Messenger; D054389:Receptors, CCR1; D019713:Receptors, CCR5; D011956:Receptors, Cell Surface; D019707:Receptors, Chemokine; C495370:Tlr9 protein, mouse; D051217:Toll-Like Receptor 9